Clinical Trial Update: Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

View source ↗

Summary

A clinical trial update reporting real-world outcomes of two combination therapies—nivolumab+ipilimumab and pembrolizumab+lenvatinib—in US patients with advance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Renal Cell Carcinoma (aRCC) | Status: COMPLETED